The 1 analysts offering 12-month price forecasts for Immunitybio Inc have a median target of 25.00, with a high estimate of 25.00 and a low estimate of 25.00. The median estimate represents a +221.75% increase from the last price of 7.77.
The current consensus among 1 polled investment analysts is to Buy stock in Immunitybio Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.20
Reporting Date Dec 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.